公开(公告)号：US20200291405A1

公开(公告)日：2020-09-17

申请号：US16801373

申请日：2020-02-26

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： Gregory Hinkle ,  Laura Sepp-Lorenzino ,  Vasant R. Jadhav ,  Martin A. Maier ,  Muthiah Manoharan ,  Stuart Milstein ,  Svetlana Shulga Morskaya ,  Kallanthottathil G. Rajeev ,  Huilei Xu

IPC: C12N15/113 ,  A61K31/713 ,  A61K45/06

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.

公开(公告)号：US20240294911A1

公开(公告)日：2024-09-05

申请号：US18509453

申请日：2023-11-15

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： James Butler ,  Kevin Fitzgerald ,  Gregory Hinkle ,  Brian Bettencourt ,  Huilei Xu

IPC: C12N15/113 ,  A61P5/06

CPC classification number: C12N15/113 ,  A61P5/06 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3341 ,  C12N2310/3515

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.

公开(公告)号：US11434487B2

公开(公告)日：2022-09-06

申请号：US16939119

申请日：2020-07-27

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： Kevin Fitzgerald ,  Huilei Xu ,  Gregory Hinkle

IPC: C12N15/113 ,  A61K31/713 ,  A61K47/54

Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.

公开(公告)号：US20200277599A1

公开(公告)日：2020-09-03

申请号：US16601681

申请日：2019-10-15

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： James Butler ,  Kevin Fitzgerald ,  Gregory Hinkle ,  Brian Bettencourt ,  Huilei Xu

IPC: C12N15/113 ,  A61P5/06

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.

公开(公告)号：US20210002638A1

公开(公告)日：2021-01-07

申请号：US16939119

申请日：2020-07-27

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： Kevin Fitzgerald ,  Huilei Xu ,  Gregory Hinkle

IPC: C12N15/113 ,  A61K31/713 ,  A61K47/54

Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.

公开(公告)号：US10767177B2

公开(公告)日：2020-09-08

申请号：US16002034

申请日：2018-06-07

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： Kevin Fitzgerald ,  Huilei Xu ,  Gregory Hinkle

IPC: C12N15/113 ,  A61K31/713 ,  A61K47/54

Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.

公开(公告)号：US20170349901A1

公开(公告)日：2017-12-07

申请号：US15591558

申请日：2017-05-10

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： Gregory Hinkle ,  Laura Sepp-Lorenzino ,  Vasant Jadhav ,  Martin Maier ,  Muthiah Manoharan ,  Stuart Milstein ,  Svetlana Shulga Morskaya ,  Kallanthottathil G. Rajeev ,  Huilei Xu

IPC: C12N15/113 ,  A61K31/713

CPC classification number: C12N15/1131 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/335 ,  C12N2310/3515 ,  C12N2310/3521 ,  C12N2310/3533

Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.

公开(公告)号：US20250034570A1

公开(公告)日：2025-01-30

申请号：US18738165

申请日：2024-06-10

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： Kevin Fitzgerald ,  Huilei Xu ,  Gregory Hinkle

IPC: C12N15/113 ,  A61K31/713 ,  A61K47/54

Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting epression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.

公开(公告)号：US20180273955A1

公开(公告)日：2018-09-27

申请号：US16002034

申请日：2018-06-07

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： Kevin Fitzgerald ,  Huilei Xu ,  Gregory Hinkle

IPC: C12N15/113 ,  A61K31/713 ,  A61K47/54

Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.

公开(公告)号：US20180201929A1

公开(公告)日：2018-07-19

申请号：US15743349

申请日：2016-07-08

Applicant: Alnylam Pharmaceuticals, Inc.

Inventor： James Butler ,  Kevin Fitzgerald ,  Gregory Hinkle ,  Brian Bettencourt ,  Huilei Xu

IPC: C12N15/113 ,  A61P5/06

CPC classification number: C12N15/113 ,  A61P5/06 ,  C12N15/1136 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/3341 ,  C12N2310/3515 ,  C12N2310/3521 ,  C12N2310/3533

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.